Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)262.13K
Market Cap
$195.70M
Enterprise Value$159.39
Total Cash (Recent Filing)$115.04M
Total Debt (Recent Filing)$42.21M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Nov 18, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.01
Shares Outstanding14,725,646
10 Day Avg. Volume177,891
30 Day Avg. Volume262,130
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside32.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$562.50K
Bulls Say, Bears Say
Bulls Say
Proprietary RNA-editing Platform & Pipeline ExpansionKorro’s OPERA RNA-editing platform is being actively expanded with KRRO-111 and a planned third GalNAc-conjugated program. Platform-driven nomination increases program throughput and liver-targeted delivery, strengthening sustainable pipeline depth and long-term R&D productivity.
Regulatory Progress (Orphan Drug)EMA Orphan Drug Designation for KRRO-121 provides regulatory incentives and potential exclusivity that materially de-risks the lead program. This structural regulatory status supports development economics, partner interest, and long-term commercial optionality for a specialized indication.
Relatively Healthy Balance Sheet And RunwayA cash balance near $138M and projected runway into H2 2028, combined with moderate leverage (equity > debt, D/E ~0.36), gives Korro multi-year funding visibility to advance clinical milestones and reduces immediate refinancing pressure while it executes on key pipeline readouts.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$68M TTM) indicates durable cash consumption consistent with early-stage biotech. Continued burn means the company remains dependent on external financing or milestone-based partnerships to fund development beyond current runway if development timelines extend.
Limited Revenue Scale And DeclineRevenue is modest, volatile and declined materially year-over-year (~38% TTM), showing no commercial diversification. Lack of material product revenue leaves value creation tied to future clinical success, increasing execution risk and lengthening the time until self-sustaining cash generation.
Funding And Dilution Risk From Capital SwingsHistorical capital-base volatility (including prior negative equity) and recent actions creating pre-funded warrants highlight reliance on capital markets and complex financing. Recurrent dilution or structured financings can erode shareholder value and impact strategic flexibility over the medium term.
Korro Bio News
KRRO FAQ
What was Korro Bio, Inc.’s price range in the past 12 months?
Korro Bio, Inc. lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio, Inc.’s market cap?
Korro Bio, Inc.’s market cap is $195.70M.
When is Korro Bio, Inc.’s upcoming earnings report date?
Korro Bio, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 94 days.
How were Korro Bio, Inc.’s earnings last quarter?
Korro Bio, Inc. released its earnings results on Aug 06, 2026. The company reported -$1.07 earnings per share for the quarter, beating the consensus estimate of -$1.338 by $0.268.
Is Korro Bio, Inc. overvalued?
According to Wall Street analysts Korro Bio, Inc.’s price is currently Undervalued.
Does Korro Bio, Inc. pay dividends?
Korro Bio, Inc. does not currently pay dividends.
What is Korro Bio, Inc.’s EPS estimate?
Korro Bio, Inc.’s EPS estimate is -1.26.
How many shares outstanding does Korro Bio, Inc. have?
Korro Bio, Inc. has 14,725,646 shares outstanding.
What happened to Korro Bio, Inc.’s price movement after its last earnings report?
Korro Bio, Inc. reported an EPS of -$1.07 in its last earnings report, beating expectations of -$1.338. Following the earnings report the stock price went up 5.391%.
Which hedge fund is a major shareholder of Korro Bio, Inc.?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (32.04% Upside)
$19.00 (32.04% Upside)
Blogger Sentiment
Neutral
KRRO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 409.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $78.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.41%
Trailing 12-Months
Company Description
Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$19.00
▲(32.04% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―